drugset / Trial / NCT00918398

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

NCT00918398

Phase 1 Completed 14 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The primary objective is to investigate the pharmacokinetics of AZD1981 given in different formulations and to measure renal clearance

Timeline

Start
2009-06
Primary completion
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1981 Small molecule 100 mg Intravenous
Subject AZD1981 Small molecule 500 mg Intravenous
Subject AZD1981 Small molecule 514 mg Intravenous

Indications

No indication recorded.